Recursion Pharmaceuticals (RXRX) CFO Taylor gave up 5,396 shares at $3.41 to cover taxes or an exercise price
Insider transactions reported
Ben R Taylor (Chief Financial Officer at Recursion Pharmaceuticals Inc., RXRX) reported that they gave up 5,396 shares at $3.41 to cover taxes or an exercise price on Sep 15, 2026. After these transactions the filing shows 1,071,462 shares held directly.
- Reporting person
- Taylor Ben R
- Role
- Chief Financial Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Shares withheld for taxes or exercise price (F) | Class A Common Stock1 | -5,396 | $3.41 | $18.4K | 1,071,462 direct |
Holdings before and after
- Class A Common Stock: 1,076,858 to 1,071,462 direct
Footnotes from the filing
- 1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Transaction codes in this filing
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Taylor report in this RXRX Form 4?
Ben R Taylor (Chief Financial Officer at Recursion Pharmaceuticals Inc., RXRX) reported that they gave up 5,396 shares at $3.41 to cover taxes or an exercise price on Sep 15, 2026. After these transactions the filing shows 1,071,462 shares held directly.
How many RXRX shares does Taylor hold after this filing?
The filing shows 1,071,462 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code F mean on an SEC Form 4?
Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
Historical context for RXRX
Across the 23 sessions after earlier RXRX headlines, the stock closed higher 10 times and lower 12 times, with a median move of 4.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RXRX | SPY |
|---|---|---|---|
| Aug 5, 2026 | Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | -4.2% | -0.2% |
| Aug 4, 2026 | Recursion to Participate in Upcoming Investor Conferences | +4.1% | +1.8% |
| Aug 3, 2026 | Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | +6.0% | +1.4% |
| Jul 29, 2026 | Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th | -2.6% | -1.5% |
| Jun 2, 2026 | Recursion to Participate in Upcoming Investor Conferences | -4.7% | +0.1% |
| Jun 1, 2026 | Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | +5.6% | +0.3% |
Earlier insider filings at RXRX
- Sep 10, 2026CEO and President Khan Najat sold $78,822 worth of shares (22,408 units at $3.52) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,072,890 units (SEC Form 4)
- Sep 2, 2026Director Borgeson Blake sold $100,200 worth of shares (30,000 units at $3.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,158,287 units (SEC Form 4)
- Aug 18, 2026CEO and President Khan Najat covered exercise/tax liability with 80,498 shares, decreasing direct ownership by 4% to 2,095,298 units (SEC Form 4) (withholding tax)
- Aug 18, 2026Chief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,076,858 units (SEC Form 4) (for withholding tax)
- Aug 18, 2026Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,043,837 units (SEC Form 4) to cover taxes
Keep researching RXRX
- RXRX insider tradesEvery buy and sale reported by Recursion Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- RXRX earnings historyPast Recursion Pharmaceuticals Inc. earnings releases, newest first.
- RXRX financial statementsRevenue, profit, cash flow and balance sheet from Recursion Pharmaceuticals Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Follow RXRX and get a push notification the moment its next story breaks.